Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ARESTOCAINE HYDROCHLORIDE vs ANOQUAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Arestocaine hydrochloride is a local anesthetic of the amide type. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthesia.
Guanabenz is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, leading to decreased peripheral vascular resistance and lowered blood pressure.
Local or regional anesthesia for dental procedures,Infiltration anesthesia,Nerve block anesthesia
Hypertension
2-5 mg/kg intramuscularly every 60-90 minutes, not to exceed 500 mg total dose in a 12-hour period.
100 mg orally twice daily
Terminal elimination half-life is approximately 1.5–2 hours in adults with normal hepatic and renal function; prolonged in hepatic impairment or congestive heart failure.
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-48 hours in severe renal impairment (Cr Cl <30 m L/min).
Primarily metabolized by the liver via hydrolysis by esterases (though it is an amide, it may be partially hydrolyzed) and conjugation. The major metabolic pathways involve CYP1A2 and CYP3A4.
Hepatic metabolism via oxidation and conjugation; metabolites excreted renally.
Renal excretion of unchanged drug and metabolites; approximately 90% excreted in urine as parent compound and metabolites (60% as unchanged drug, 30% as metabolites), with less than 10% fecal elimination.
Renal excretion accounts for approximately 70% of the dose (50% as unchanged drug, 20% as inactive metabolites); biliary/fecal excretion accounts for 30%.
Approximately 70% bound primarily to alpha-1-acid glycoprotein (AAG) and to a lesser extent albumin.
Approximately 90% bound to albumin.
Volume of distribution is 0.8–1.5 L/kg, reflecting extensive tissue distribution; higher in neonates and infants.
0.8-1.2 L/kg, indicating extensive distribution into total body water.
Topical: variable, approximately 30–50% absorbed through intact skin; Oral: negligible due to extensive first-pass metabolism (bioavailability <10%); Intravenous: 100%.
Oral: 60-70% due to first-pass metabolism.
GFR 30-50 m L/min: reduce dose by 25%; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use.
GFR 30-50 m L/min: 100 mg once daily; GFR <30 m L/min: 50 mg once daily; not recommended for GFR <15 m L/min
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: 50 mg twice daily; Child-Pugh C: not recommended
1-3 mg/kg intramuscularly every 60-90 minutes, max 200 mg per dose; maximum cumulative dose 400 mg/12 hours.
Not approved for pediatric use; no established dosing
Initiate at lowest effective dose (2 mg/kg) due to increased sensitivity and potential for prolonged duration; monitor for adverse effects.
No specific adjustment; monitor renal function and consider reduced initial dose (50 mg twice daily) in patients >65 years with renal impairment
There is no FDA black box warning for Arestocaine hydrochloride.
No FDA black box warning.
Risk of systemic toxicity if injected intravascularly,Use with caution in patients with hepatic impairment,Use with caution in patients with cardiovascular disease,Risk of methemoglobinemia in patients with glucose-6-phosphate dehydrogenase deficiency
Rebound hypertension upon abrupt discontinuation; sedation and drowsiness; potential for orthostatic hypotension; caution in patients with severe coronary insufficiency or cerebrovascular disease.
Hypersensitivity to amide-type local anesthetics,Severe hypotension,Myasthenia gravis (relative contraindication),Bradycardia
Known hypersensitivity to guanabenz; patients with severe hepatic or renal impairment.
No specific food interactions; avoid hot foods until numbness resolves to prevent burns.
Avoid grapefruit and grapefruit juice as they may increase quinine levels. Take with a full glass of water. May be taken with meals to reduce nausea.
Pregnancy Category C. Animal reproduction studies have not been conducted. In first trimester, limited data; potential for adverse effects on fetal development cannot be excluded. In second and third trimesters, risk of placental transfer and fetal bradycardia; use only if clearly needed.
Pregnancy Category X. Anoquan is contraindicated in all trimesters. In the first trimester, there is a high risk of major cardiac malformations and neural tube defects. Second and third trimester exposure is associated with fetal nephrotoxicity, oligohydramnios, and premature closure of the ductus arteriosus.
No data on excretion in human milk. M/P ratio unknown. Caution advised; discontinue breastfeeding or drug based on importance of drug to mother.
Excreted in human milk. M/P ratio not determined. Avoid breastfeeding due to potential for serious adverse reactions in the nursing infant, including renal impairment and electrolyte disturbances.
Increased plasma volume and decreased plasma protein binding may require dose adjustments. However, no established guidelines; use lowest effective dose and shortest duration.
Anoquan is contraindicated in pregnancy; no dose adjustments are recommended because use during pregnancy is not advised.
ARESTOCAINE HYDROCHLORIDE (presumed anesthetic) is not a recognized drug; likely a misspelling of articaine or similar. If referring to articaine, clinical pearls: 1) Onset within 1-3 minutes, duration 1-3 hours; 2) Metabolized by plasma esterases, caution in pseudocholinesterase deficiency; 3) Maximum dose 7 mg/kg (adults) to avoid CNS/cardiac toxicity; 4) Contains sulfites, avoid in allergic patients.
ANOQUAN (quinine sulfate) is used for uncomplicated Plasmodium falciparum malaria. Monitor for cinchonism (tinnitus, headache, nausea). Avoid in G6PD deficiency due to hemolysis risk. Correct hypoglycemia frequently. Use with caution in atrial fibrillation due to QT prolongation.
Avoid chewing or biting lips/cheeks while numb to prevent injury.,Report any signs of allergic reaction (rash, swelling, difficulty breathing) immediately.,Do not consume hot foods or beverages until sensation returns.,Inform dentist of all medications, especially MAOIs or anticoagulants.
Take with food to reduce gastrointestinal upset.,Complete full course even if symptoms improve.,Report ringing in ears, confusion, or vision changes.,Avoid driving if dizziness or visual disturbances occur.,Inform doctor of any history of G6PD deficiency or cardiac arrhythmias.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ARESTOCAINE HYDROCHLORIDE vs ANOQUAN, answered by our medical review team.
ARESTOCAINE HYDROCHLORIDE is a Local Anesthetic that works by Arestocaine hydrochloride is a local anesthetic of the amide type. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthesia.. ANOQUAN is a Local Anesthetic that works by Guanabenz is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, leading to decreased peripheral vascular resistance and lowered blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ARESTOCAINE HYDROCHLORIDE and ANOQUAN depend on the specific clinical indication. These are both Local Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ARESTOCAINE HYDROCHLORIDE is: 2-5 mg/kg intramuscularly every 60-90 minutes, not to exceed 500 mg total dose in a 12-hour period.. The standard adult dose of ANOQUAN is: 100 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ARESTOCAINE HYDROCHLORIDE and ANOQUAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ARESTOCAINE HYDROCHLORIDE is classified as Category C. Pregnancy Category C. Animal reproduction studies have not been conducted. In first trimester, limited data; potential for adverse effects on fetal development cannot be excluded. . ANOQUAN is classified as Category C. Pregnancy Category X. Anoquan is contraindicated in all trimesters. In the first trimester, there is a high risk of major cardiac malformations and neural tube defects. Second and . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.